Champion Exceptional Entrepreneurs
in Healthcare and Life Science.


K2 Venture Partners is a venture capital fund founded in 2016, focusing on investment in BioTech, MedTech, and life-science companies in early-stage. We support, empower, and resource exceptional scientists and entrepreneurs worldwide to translate innovative technology platforms into valuable, high-impact therapeutics and applications. We strive to be the most important institutional investors, provide hands-on support and serve as long-term partners.

Dr. ZHAO Baiteng Founder of ProfoundBio

ProfoundBio’s vision is to develop novel targeted therapeutics with curative potential for cancer patients. Thanks to K2 Venture Partners leading the first institutional investment, we have established fully integrated ADC R&D capabilities and transitioned into a clinical-stage company. Our next-generation novel and proprietary technology platform has the potential to further improve the efficacy and safety profiles of ADCs.

Dr. Zhao Baiteng brings many years of working experience in both large pharma and small biotech companies. Prior to cofounding ProfoundBio he was responsible for the overall modeling and simulation strategies for the development pipeline and supported both preclinical and clinical development of ADC drug candidates at Seagen. Before joining Seagen in 2009, he worked at Merck (MRL, USA) and supported the clinical pharmacology, drug metabolism, and pharmacokinetics for multiple clinical development programs in several therapeutic areas. Dr. Zhao obtained his Ph.D. degree in Pharmaceutics from the University of Texas at Austin and B.S. degree in Biology from Peking University. He completed his post-doctoral training at the Department of Pharmaceutical Sciences, State University of New York at Buffalo. Dr. Zhao has authored ten plus peer-reviewed papers and contributed to one book chapter on ADCs and is an inventor of several ADC patents.

Dr. WANG Weimin Founder of SanegeneBio

SanegeneBio is committed to the R&D of the next generation siRNA drugs. We hope to contribute to the well-being of human by providing innovative solutions for patients and filling unmet medical needs.

Dr. WANG Weimin, chairman and founder of SanegeneBio. He is one of the industry’s leading oligonucleotide chemists with over 20 years of oligonucleotide research experience. Before founding SanegeneBio, Dr. Wang worked at Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2021) as the Executive Director of Chemistry. His team pioneered Dicerna’s liver targeting GalXC technology as well as extrahepatic delivery platforms. Prior to joining Dicerna, Dr. Wang joined Merck & Co. through its $1.1 billion acquisition of Sirna, where he developed the world’s first lipid nanoparticle delivery platform for nucleic acid therapeutics. During his tenure at Dicerna, Merck and Sirna, Dr. Wang evaluated over 500 external opportunities for nucleic acid drug discovery and delivery technology, and managed numerous major partnerships, including Eli Lilly, Roche, Novo Nordisk, Boehringer Ingelheim, Alexion, etc.

Dr. WU Zhenhua Founder of Exegenesis Bio

We are fortunate to have K2 Venture Partners' backing since the angel round. K2 provided not just funding but also comprehensive support, including talent recruitment, legal counsel and connecting various potential partnerships. They have always supported us and been truly an essential part of the growth of ExegenesisBio.

Dr. WU Zhenhua is the founder, chairman and CEO of Exegenesis Bio. Before founding Exegenesis, he was CEO of NeuExcell Therapeutics, where he was responsible for the overall operations and business activities. He previously served as VP, Head of Preclinical Development at United Neuroscience Inc., where he was responsible for the strategy formulation and implementation of all preclinical R&D activities. Prior to that, Dr Wu served as Director, Drug R&D Department of Neuroscience at GSK, focusing on the development of gene therapy, small molecule drugs in preclinical & early clinical stage for neurodegenerative and neuroinflammatory diseases. Before joining GSK, Dr. Wu worked in multiple functional departments at Merck for nearly 10 years. He led R&D projects of various kinds of neuroscience drugs and successfully advanced these into preclinical & clinical stage. Dr. WU Zhenhua received his PhD in Neuroscience from the University of Rochester and his MS in Cell Biology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences. Dr. Zhenhua Wu received his bachelor degree of biology from Lanzhou University. He has published several high-quality papers in neuroscience in prestigious journals, such as Nature Medicine, Neuron and Stroke. Dr. Zhenhua Wu also serves as the President of the American Chinese Pharmaceutical Association Greater Philadelphia (SAPA-GP) (2016-2018) and is a member of the Board of Directors of the American Chinese Pharmaceutical Association (SAPA).

Dr. WANG Zefeng Founder of Circode

The breakthrough application of biotechnology requires profound sensitivity and forward thinking from both scientific entrepreneurs and investors. K2 Venture Partners can see both the breakthroughs and challenges of RNA technologies, which is of great help to me.

Dr. WANG Zefeng received his B.Sc. fromTsinghua University and PhD from Johns Hopkins Medical School. After working as a postdoc at Massachusetts Institute of Technology, he moved to the University of North Carolina Chapel Hill and later achieved tenure position. He worked as the director of the CAS-MPG Partner Institute for Computational Biology (PICB), and the director of the Laboratory of Computational Biology, Chinese Academy of Sciences in 2015. He is now a Principal Investigator at Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences. Dr. Wang has long been working in the field of RNA systems biology and related technologies.

He is the first to discover that circular RNA is translatable in cells, also the first to identify atypical RNA translation regulatory elements systematically, paving the path for applying circular RNA as a new generation of mRNA therapy.

Dr. Wang has won a number of awards both internationally and locally, including Jefferson-Pilot Fellowships in Academic Medicine Award, Beckman Young Investigator Award, Kimmel Scholar Award, Alfred Sloan Research Fellow, Max Planck Scholar Award, German Mercator Scholar, Top Talent in the Chinese Academy of Sciences First Action Hundred Talents Program, Ministry of Science and Technology Innovation Team in Key Fields Person in charge, the leading talents in scientific and technological innovation of special support plan, etc. He is an invited editorial board member of Science Bulletin, Fundamental Research, JMCB and several academic journals. He is also a member of academic committees of several national laboratories of the Chinese Academy of Sciences.

Dr. WU Yuxuan Founder of YolTech

We really appreciate K2 Venture Partners' support. They helped us grow rapidly through their savvy industry expertise and abundant connections. We believe that in vivo gene editing therapeutics will become a new generation of drugs, covering both rare and common diseases and benefiting a large population of patients.

Dr. WU Yuxuan, researcher at the School of Life Sciences of East China Normal University, previously co-founder of BRL Medicine. Dr. Wu founded YolTech in 2021 to develop a new generation of mRNA-based gene editing therapeutics. Graduated from Wuhan University, Dr.Wu worked as a postdoctoral fellow and associate research fellow at the Shanghai Institute of Biochemistry and Cells, Chinese Academy of Sciences. During his work at Harvard Medical School, he developed and optimized a CRISPR/Cas9-based gene editing system in hematopoietic stem cells. During his work at BRL Medicine, he developed the world's first CRISPR/Cas9 gene editing treatment for β0/β0 thalassemia patients, also the first gene editing treatment case for severe beta thalassemia in Asia.

Dr. AU Kwok Wai Founder of Cornerstone

CornerStone is dedicated to building safe and efficient technology platforms for surgical robotics. Through ingenuity and intelligent technology innovation, we expand the accessibility of high-quality medical treatments and services, improving the accuracy and efficiency of surgical operations.

Dr. AU Kwok Wai, Samuel, Ph.D. from Massachusetts Institute of Technology (MIT), worked for Intuitive Surgical Company, led and participated in the development of several core products of da Vinci. Dr. Au mastered the key technologies of surgical robots, and has more than 15 patents in the US. Dr. Au is the Professor of Mechanical and Automation Engineering of the Chinese University of Hong Kong, the Co-Chairman of Innovative Medical Robotics Center of Chinese University of Hong Kong and the Founder and President of Cornerstone Robotics.

Cornerstone Robotics is a leading innovative surgical robot R&D company in China. Cornerstone has completed the multi-pipeline layout of soft tissue surgical robots and other major specialized surgical robots. The first-generation porous laparoscopic surgical robot independently developed by Cornerstone Robotics has entered the clinical trial stage, and will apply for medical device certification worldwide, providing safe and efficient surgical robots for the world and introducing Chinese power into the global surgical robot market.

  • Exegenesis Bio is an innovative biotech company that provides accessible gene therapy for patients around the world. Exegenesis Bio was founded in Hangzhou, China in 2019. The company's AAV gene therapy EXG001-307 for SMA Type I, delivered via i.v., is the first one to have entered clinical trials in China. Based on innovative vectors such as AAV and lenti virus, the company has built a strong pipline of multiple programs, with fully integrated manufaturing capabiltiies, targeting diseases in liver, ophthamology and CNS. The founding team has extensive leadership experience at leading US and Global gene and cell therapy companies across all functional areas.

    K2 Venture Partners led the angel round of financing in early 2019 and was deeply involved in the company's establishment, and continued to support it through subsequent rounds.

  • Founded in Suzhou, 2019, ProfoundBio is a biotech company focusing on discovering and advancing novel classes of therapeutics that are designed to leverage the immune system to eradicate cancer. Based on its innovative drug-linker technology, Profound Bio has developed a new generation platform of antibody-drug conjugate with better tissue penetration and wider therapeutic windows. The company's pipeline focuses on drugs treating solid tumors.

    The founding team of Profound Bio are all antibody-drug conjugate (ADC) industry veterans with decades of research and development experience handling this powerful class of drugs.

    K2 Venture Partners lead the Pre-A round of financing in 2020.

  • SanegeneBio is a global RNAi innovator founded in Suzhou, China and Boston, US in 2021. The company has established its own RNAi platform based on its proprieatory technology in nucleic acid modification and drug delivery. The platform has been validated with enhanced gene silencing with great safety profiles across different tissues. It will be applied to treat both common and rare diseases in metabolism, oncology, immunology, ophthalmology, as well as central nervous system.

    The founding team consists of pioneering scientists with decades of industry experience in the RNAi field. The team has profound and comprehensive experience in research and development.

    K2 Venture Partners invested in SanegeneBio as the sole investor in early 2021 in its angel round, and was greatly involved in the company launch. It has also continued supporting the company in its subsequent rounds.

  • Founded in Suzhou, China in 2021, RinuaGene is a mRNA platform company. Based on its self-developed technology of mRNA design, chemical modification and LNP delivery, RinuaGene has developed a comprehensive platform that ahieves globally top levels of delivery efficiency, tissue specificity, and protein expression stability. The platform will be used to design and develop infectious diseases vaccines and therapies for cancer.

    The founding team have decades of industry experience in innovative drug research and development covering early discovery, manufacturing and development.

    K2 Venture Partners participated in the establishment of the company and led the Pre-A round of financing in 2021.

  • Founded in Shanghai and San Diego in 2021, GluBio Therapeutics is a biotech company focused on developing novel targeted protein degradation (TPD) drugs. The company develops next-generation molecular glues and PROTACs for many of the previously "undruggable" targets. It has built a strong pipeline with multiple first-in-class and best-in-class programs, several of which treating blood cancer and solid tumors have entered preclinical and IND-enabling stage.

    The founding team have deep knowledge and expertise in the field, covering all functional areas in TPD drug discovery.

    K2 Venture Partners participated in its Series Angel Financing in 2021.

  • Founded in Shanghai, 2021, YolTech Therapeutics is committed to the development of a new generation of in vivo gene editing combining mRNA delivery and gene editing. The company has built a strong pipeline targeting genetic diseases and cardiometabolic diseases, through the continuous optimization of editing tools including CRISPR, base editing and other next-generation editors, together with its innovative improvement on mRNA and LNP delivery.

    The core team includes well-known scientists in the field of gene editing, Dr. Yuxuan Wu, a principal investigator at the School of Life Sciences of East China Normal University, and several senior scientists from academia and industry. The core members enjoy extensive expertise across key functional areas including gene editing, delivery system targeting multiple tissue types, and manufacturing process.

    K2 Venture Partners invested in its Series Angel as the sole institutional investor in 2021 and was deeply involved in the company's establishment. It has continuously supported the company in subsequent rounds.

  • LTZ therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need, founded in Shenzhen, China in 2021. LTZ therapeutics is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging biology of tumor microenvironment -- breaking new ground in the biotech industry in both China and worldwide.

    The founding team and the scientific advisory committee have profound accumulation and successful experience in various aspects of immunooncology, tumor microenvironment regulation, protein drug design and clinical translation.

    K2 Venture Partners led the Pre-A round of financing in 2021 and was deeply involved in the company establishment.

  • Founded in 2016, Phanes Therapeutics is a biotechnology company focusing on the research and development of drugs in immunoncology and ophthalmology, operated in Shanghai, China and San Diego, US. Based on its propriatary antibody technology platforms PACbody™, ATACCbody™ and SPECpair™, the company has built a strong pipline portfolio of first-in-class and best-in-class programs. Both the bispecific antibody programs PT217 and PT886 have been granted orphan drug designation by the US FDA.

    Phanes Therapeutics was founded by Dr. Ming Wang, former VP of Johnson & Johnson. The founding team also includes a number of senior scientists who have worked at Pfizer, Amgen and other Big Pharma, with decades of experience in drug development.

    K2 Venture Partners led its Series A financing in 2018.

  • GluBio Pharmaceutical is a new drug research and development company focusing on proteolysis targeting chimera (PROTAC). It was established in Shanghai, China and San Diego, USA in 2021. GluBio Pharmaceutical develops a new generation of molecular glue and PROTAC drugs for pathogenic targets that were previously considered "undruggable". The company has laid out multiple pipelines with first-in-class and best-in-class potential and built an innovative platform based on molecular glue and new target discovery technology. Multiple drugs for the treatment of hematological tumors and solid tumors have entered the preclinical research stage.

    GluBio Pharmaceutical's founding team has rich experience and technical expertise in PROTAC and their professional background and practical experience cover all aspects of the development of such drugs.

    K2 Venture Partners participated in its angel round financing in 2021.

  • Founded in Suzhou, China in 2021, Neuro3 Therapeutics is a biotech company focusing on developing innovative therapeutics treating central nervous system diseases.

    The company is committed to the development of technology platforms that can penetrate the blood-brain barrier as well as the development of small molecules. The founding team has extensive experience in all the functional areas of drug development for central nervous system diseases.

    K2 Venture Partners led the Series Pre-A Financing in 2021 and was deeply involved in the company establishment.


  • Founded in Beijing in 2017, Sironax is a clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple first-in-class or globally leading programs, including both small molecule and biologics. The lead RIPK1 program is comprised of several chemically differentiated small molecule inhibitors, including SIR0365—which has completed two Phase 1b patient studies—in addition to SIR2446, which is now in a Phase 1a study in healthy volunteers.

    Sironax was co-founded by Dr. Xiaodong Wang and Dr. Zhang Zhiyuan. Dr. Wang is a member of United States National Academy of Sciences and the Howard Hughes Medical Institute, a foreign academician of the Chinese Academy of Sciences and the director of the National Institute of Biological Sciences, Beijing. Dr. Zhang Zhiyuan is a senior researcher at the National Institute of Biological Sciences, Beijing. The leadership team have extensive experience of R&D and management in the biopharmacuetical industry.

    K2 Venture Partners participated in its series A financing in 2018.

  • PrimeGene Therapeutics is an innovative specialty pharma company focusing on discovery, development and commercialization of innovative therapies, especially external medicines, for immune/inflammatory diseases in dermatology and ophathamology. PrimeGene Therapeutics was founded in Beijing, China in 2016. The founding team has decades of industry expertise in all functional areas from early discovery through commercialization.

    K2 Venture Partners invested in PrimeGene Therapeutics in 2021 and continously supported in subsequent rounds.

  • SpearBio is an innovative developer of small-sample, ultrasensitive protein-detection technology that uses just a finger prick or dried blood samples to empower disease research, patient care, and drug development.

    The founder, Professor Peng Yin, a world-renowned scientist of DNA nanotechnology, is from the Wyss Institute of Harvard University and has been published in multiple papers in Nature, Science, and Cell.

    The DNA-nanotechnology driven SPEAR technology is superior to other protein detection assays in its combination of extreme sensitivity, wash-free workflow, high dynamic range, small volume, low cost and the fact that it can be read out using common quantitative PCR equipment. SpearBio is working towards commercializing the NAB-Sure™ SARS-CoV-2 test kit, which is the world’s first assay to accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples.

    K2 Venture Partners invested in SpearBio in 2022.

  • Eyebright Medical (688050) is an innovative ophthalmic medical device company, mainly developing products in both surgery and optometry. The core products of Eyebright include intraocular lenses for surgery, orthokeratology lenses for optometry and a series of supporting products. Eyebright aims at developing a full range of ophthalmic medical products, such as implantable ophthalmic consumables, surgical instruments, surgical equipment, optometry products, ophthalmic preparations etc., covering cataracts, refractive errors, glaucoma, fundus lesions and other fields as an innovative leader in the domestic ophthalmic medical field.

    K2 Venture Partners participated in the D round of financing in 2018.

  • Cornerstone Robotics is a leading innovative surgical robot R&D company founded in Shenzhen, China and Hong Kong, China in 2019.

    The first-generation porous laparoscopic surgical robot independently developed by Cornerstone Robotics has entered the clinical trial stage in 2022, and has completed the first batch of human clinical trials. Cornerstone Robotics actively leverages the advantages of its technology platform to simultaneously expand into other areas of specialized surgery.

    The R&D team of Cornerstone Robotics is composed of the world's top surgical robot experts scientists in the industry, while the size of the plants for mass manufacturing is continuously growing, as is the high-level business team.

    K2 Venture Partners participated in Cornerstone Robotics's A round of financing and continued to support subsequent rounds of financing.

  • Richen Force Holdings is an innovative medical device company focusing on the research and development of digestive tract disease detection instruments, established in Beijing, China in 2002. In the field of breath test, Richen Force Holdings is the earliest player in China that has obtained SFDA approval as well as CE certification and has independent intellectual property rights that can simultaneously produce the equipment and reagents. The Carbon13 breath test diagnostic system developed by the company is the gold standard written into clinical guidelines for the detection of Helicobacter pylori because of its high sensitivity and specificity. Richen Force Holdings continuously launched new products such as capsule endoscopes and disposable endoscopes.

    K2 Venture Partners participated in the company's B round of financing in 2016 and continues to support subsequent rounds of financing.

  • Derism develops innovative blood glucose monitoring sensor CGM. Derism was established in Beijing in 2020.

    Based on the self-developed platform of CGM material process technology, Derism has abundant technical accumulations in terms of the upgraded blood glucose electrode-sensing system, the efficient processing and the highly-stable semi-permeable membrane. The product of Derism can be exempted from in-plant calibration while ensuring the performance to be the same level as the world's leading competitors for 14 days. The founding team of the company has first-line CGM design and production experience in major overseas factories.

    K2 Venture Partners has participated in Derism's Pre A and A rounds of financing.

  • Tendfo develops innovative interventional medical devices focusing on thrombus removal. Tendfo was founded in Shanghai in 2020.

    Tendfo conducts the first clinical research on interventional thrombectomy stents for acute pulmonary embolism. The self-developed pulmonary artery thrombus removal system Tendvia™ is currently in the clinical trial stage. The second core product, a scavenging system of deep vein thrombosis , has entered clinical trials in 2022.

    The founder of Tendfo has more than 10 years of R&D experience of endovascular interventional devices. The core team has also worked on multiple types of cardiovascular and cerebrovascular interventional medical devices.

    K2 Venture Partners participated in Tendfo's Pre-A round and A round of financing.

  • Agilis Robotics a leading developer of flexible robotic instruments designed to support endoscopic surgery, established in Hong Kong, China in 2021. Agilis Robotics also has branches in Shenzhen and Guangzhou.The self-developed flexible robot arm is the world's smallest known robot and the only product that are compatible with all kinds of endoscopes worldwide. Research and development progress is at the leading level in the world. Agilis Robotics has completed their first animal test at CUHK, successfully resecting artificial bladder tumors in a pig.

    The core team of Agilis Robotics includes scientists from the Department of Mechanical Engineering of the University of Hong Kong, senior practitioners in industry and finance, with world-leading professional level and market control.

    K2 Venture Partners participated in its A-round financing in 2022, deeply participated in the company's preparation process, and continued to support it in subsequent rounds.

  • Scisoon develops innovative diagnosis and treatment for clinical diseases utilizing molecular genetic testing and personalized health management services based on the self-developed genetic testing platform. Scisoon was founded in Beijing in 2015.

    Scisoon is commited to the vision of Closer to the Clinic in terms of oncology in reproductive health and preventive health. In the field of reproductive health, Scisoon has developed Youxinan, the leading non-invasive prenatal genetic testing system based on the self-developed Bayesian statistical algorithm.In the field of tumor diagnosis and treatment, Scisoon has dual platforms of ctDNA and CTC liquid biopsy to facilitate early tumor screening as well as medication guidance, prognosis assessment and dynamic monitoring.

    K2 Venture Partners participated in Scisoon's A round of financing in 2017.

  • Founed in Nanjing, China in 2016, LanSionBio is a company that develops, produces and sells POCT diagnostic reagents and instruments. LanSionBio owns nearly 300 core intellectual property rights. The self-developed diagnostic products can meet the comprehensive needs of clinical departments including outpatient, emergency departments and cardiology departments for tertiary hospitals and small & medium-sized medical institutions. LanSionBio has exported products to nearly 100 countries and regions.

    K2 Venture Partners participated in its A round of financing in 2018.

  • Baicare Biotechnology Co., Ltd is a biomedical high-tech enterprise which is led by microfluidic molecular diagnostic technology and integrates the research and development, production and sales of clinical test reagents and instruments. Baicare was founded in Beijing, China in 2013.

    Baicare has independently developed and designed a series of products including UltraFast QPCR system, 'Ichip' multi-index nucleic acid testing (NAT) system, 'Onestart' automatic nucleic acid testing (NAT) system, 'Microfluidic chip' for detecting the multiple respiratory tract and cerebrospinal fluid infections etc, achieving that with ‘one chip' to detect various pathogenic bacteria and Antimicrobial resistance, and providing a fast and effective basis for clinical diagnosis and treatment.

    K2 Venture Partners participated in BaiCare's A round of financing.

  • NKDPharma provides CRO services for the innovative pharmaceutics utilizing the multiple self-developed biomedical materials platform. NKDPharma was founded in Beijing in 2013.

    NKDPharma has obtained certification of ISO 9001, ISO 45001, ISO 14001, CNAS, Intellectual Property Management etc. NKDPharma has provided CRO services to more than 100 large and medium-sized pharmaceutical enterprises as well as holders of pharmaceutical marketing authorizations.

    K2 Venture Partners participated in NKDPharma's B round of financing.

  • Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics was founded in Hangzhou, China in 2015. Apollomics currently has six pipelines in clinical stages. The company reached a deal with Maxpro Capital Acquisition Corp., a Nasdaq-listed shell company, in September 2022. The deal is expected to be completed in the first quarter of 2023 and Apollomics will be listed on Nasdaq.

    K2 Venture Partners participated in the B round of financing in 2019.

  • Founded in Shanghai in 2018, Tyligand is a clinical-stage biotech company that focuses on the discovery and development of small molecule therapeutics to help patients with drug-resistant cancer.

    Relying on the in-depth understanding of biology and extensive experience in synthetic chemistry, Tyligand aims to develop highly selective small molecules to achieve multi-level, precise regulation of the signaling protein phosphorylation, and to offer safer, more effective and economical solutions to patients. The company has built a pipline with multiple Best or First -in- Class potential programs.

    K2 Venture Partners participated in the Pre-A round of financing in 2018.

  • Aureka Biotechnologies is a biotech committed to democratizing the pharmaceutical industry. The company develops a therapeutic discovery platform that uniquely integrates high-throughput, single-cell-based functional screening, synthetic biology-based autonomous discovery, and generative AI-based molecule design and multi-objective optimization. Empowered by large-scale, multi-metric data and reinforcement learning, Aureka’s AI solutions uncovers therapeutic design principles and exponentially accelerate the discovery of a wide range of macromolecule including bispecific antibodies, TCR-T, ADCs, peptides, as well as new therapeutics for previously challenging targets such as GPCRs. 

  • Spatomics, founded in 2023, is a life science tool innovation company with industrial leading expertise and exclusively licensed patents that focus on spatial omics. The company has developed the world’s first end-to-end ultrahigh-plex multi-omics platform with best-in-class sensitivity, compatibility, throughput, and cost. Spatomics is aiming to transfer the advanced spatial biology tools from research use only to widely accessible by translational and clinical applications.

    K2 Venture Partners led the Angel round of financing in 2023 and was deeply involved in the company establishment.


  • CHEN Keyi

    Founding Partner

    Before founding K2VC, Keyi was a principal at Ceyuan Venture. During his study at Peking University, Keyi was the President of the Mountaineering Association and scaled six mountains, including Mt. Everest and Mt. Cho Oyu.

  • WANG Yunhai

    Managing Partner

    WANG Yunhai is the Managing  Partner  of K2 Venture Partners. Wang holds a PhD degree in biomedical engineering and has over 10 years of experience in BioTech and BioMed sectors. He led investments of Eyebright, Exegenesis Bio, ProfoundBio, RinuaGene ect. Wang worked at Lapam Capital previously.

  • WU Yao


    WU Yao is a Partner of K2 Venture Partners. Yao mainly focus on innovative therapeutics and technology platform and led the investments of YolTech, Circode Biomed, etc. Yao holds a Master degree of Public Health from Columbia University. Yao previously worked in BDA China and L.E.K. Consulting.